Background: Critically ill patients are at high risk for nosocomial infections and resultant organ dysfunction and death. These patients typically have protracted intensive care unit (ICU) courses and consume increasingly limited resources. Enteral nutrition with specific immune-modulating components has been previously shown to improve outcomes in select populations of patients, but results have been mixed in critically ill patients. Impact 1.5 (Novartis Nutrition, Minneapolis, MN) is a commercially available enteral formula containing ingredients known to improve several parameters of immune function. We hypothesized that administration of Impact 1.5 tube feedings would reduce the incidence of nosocomial infection and ICU resources in critically ill patients admitted to the ICU for severe trauma, burns, or sepsis insults. Methods: The Impact 1.5 group (n = 17) was compared with a historical cohort of ICU patients (n = 21) of similar illness severity that received a standard high-energy enteral formula. The incidence of nosocomial infections and mortality, and the consumption of multiple ICU resources were examined. A cost analysis based on these results was then performed to determine the cost effectiveness of this proprietary immunonutrition enteral formula. Results: A pronounced reduction in nosocomial pneumonia (12% vs 52%, p< .01) was identified, with consequent trends toward a reduction in duration of mechanical ventilation and ICU length of stay. Urinary tract infections that may have less influence on ICU resources were increased in the Impact 1.5 group. No difference in mortality was identified, despite the inclusion of patients with severe sepsis in the study group. According to the average number of ICU days required for each study cohort, the Impact 1.5 group led to a cost savings of at least $193,350.00. Conclusions: ICU patients with significant illness severity experienced a decrease in the incidence of an important nosocomial infection that is commonly associated with increased use of ICU resources and length of stay. This decrease in patient morbidity led to substantial cost savings despite the small size of our study trial. (Journal of Parenteral and Enteral Nutrition 29:S62–S69, 2005)
Get full access to this article
View all access options for this article.
References
1.
1. Moore FA, Moore EE, Read RA. Postinjury multiple organ failure: role of extrathoracic injury and sepsis in adult respiratory distress syndrome.New Horiz.1993;1:538–549.
2.
2. Sheth, K, Bankey P. The liver as an immune organ.Curr Opin Crit Care.2001;7:99–104.
3.
3. Stechmiller JK, Treloar D, Allen N. Gut dysfunction in critically ill patients: a review of the literature.Am J Crit Care.1997;6:204–209.
4.
4. Mainous MR, Block EFJ, Deitch EA. Nutritional support of the gut: how and why.New Horiz.1994;2:193–201.
5.
5. Kudsk KA. Current aspects of mucosal immunology and its influence by nutrition.Am J Surg.2002;183:390–398.
6.
6. Anderson JD, Moore FA, Moore E. Enteral feeding in the critically injured patient.Nutr Clin Pract.1992;7:117–122.
7.
7. Moore FA, Feliciano DV, Andrassy RJ, et al. Early enteral feeding, compared with parenteral, reduces postoperative septic complications: the results of a meta-analysis.Ann Surg.1992;216:172–183.
8.
8. Marik PE, Zaloga GP. Early enteral nutrition in acutely ill patients: a systematic review. Crit Care Med. 2001;29:2264-2270. 9. Braunschweig CL, Levy P, Sheean PM, Wang X. Enterai compared with parenteral nutrition: a meta-analysis.Am J Clin Nutr.2001;74:534–542.
9.
10. Wyncoll D, Beale R. Immunologically enhanced enterai nutrition: current status.Curr Opin Crit Care.2001;7:128–132.
10.
11. Alvarez W, Mobarhan S. Finding a place for immunonutrition.Nutr Rev.2003;61:214–218.
11.
12. Suchner U, Kuhn KS, Fürst P. The scientific basis of immunonutrition.Proc Nutr Soc.2000;59:553–563.
12.
13. Braga M, Vignali A, Gianotti L, Cestari A, Profili M, Carlo VD. Immune and nutritional effects of early enterai nutrition after major abdominal operations.Eur J Surg.1996;162:105–112.
13.
14. Gianotti L, Braga M, Fortis C, et al. A prospective, randomized clinical trial on perioperative feeding with an arginine-, ?-3 fatty acid-, and RNA-enriched enterai diet: effect on host response and nutritional status.JPEN JParenter Enteral Nutr.1999;23:314–320.
14.
15. Kernen M, Senkal M, Homann H-H, et al. Early postoperative enterai nutrition with arginine-ü)-3 fatty acids and ribonucleic acid supplemented diet versus placebo in cancer patients: an immunologie evaluation of Impact®.Crit Care Med.1995;23:652–659.
15.
16. Braga M, Gianotti L, Cestari A, et al. Gut function and immune and inflammatory responses in patients perioperatively fed with supplemented enterai formulas.Arch Surg.1996;131:1257–1265.
16.
17. Tepaske R, Velthuis H, Oudemans-van Straaten HM, et al. Effect of preoperative oral immune-enhancing nutritional supplement on patients at high risk of infection after cardiac surgery: a randomized placebo-controlled trial.Lancet.2001;358:696–701.
17.
18. Braga M, Gianotti L, Vignali A, Di Carlo V. Preoperative oral arginine and n-3 fatty acid supplementation improves the immunometabolic host response and outcome after colorectal resection for cancer.Surgery.2002;132:805–814.
18.
19. Gianotti L, Braga M, Vignali, et al. Effect of route of delivery and formulation of postoperative nutritional support in patients undergoing major operations for malignant neoplasms.Arch Surg.1997;132:1222–1230.
19.
20. Braga M, Gianotti L, Radaelli G, et al. Perioperative immunonutrition in patients undergoing cancer surgery: results of a randomized double-blind phase 3 trial.Arch Surg.1999;134:428–433.
20.
21. Heys SD, Walker LG, Smith I, Eremin O. Enterai nutritional supplementation with key nutrients in patients with critical illness and cancer: a meta-analysis of randomized controlled clinical trials.Ann Surg.1999;229:467–477.
21.
22. Beale RJ, Bryg DJ, Bihari DJ. Immunonutrition in the critically ill: a systematic review of clinical outcome.Crit Care Med.1999;27:2799–2805.
22.
23. Oltermann MH, Rassas TN. Immunonutrition in a multidisciplinary ICU population: a review of the literature.JPEN J Parenter Enteral Nutr.2000;25(Suppl):S30–S35.
23.
24. Heyland DK, Novak F, Drover JW, Jain M, Su X, Suchner U. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence.JAMA.2001;286:944–953.
24.
25. McCowen KC, Bistrian BR. Immunonutrition: problematic or problem solving?Am J Clin Nutr.2003;77:764–770.
25.
26. Sacks GS, Genton L, Kudsk KA. Controversy of immunonutrition for surgical critical-illness patients.Curr Opin Crit Care.2003;9:300–305.
26.
27. Montejo JC, Zarazaga A, Lôpez-Martinez J, etc. Immunonutrition in the intensive care unit: a systematic review and consensus statement.Clin Nutr.2003;22:221–233.
27.
28. Kudsk KA, Minard G, Croce MA, et al. A randomized trial of isonitrogenous enterai diets after severe trauma: an immune-enhancing diet reduces septic complications.Ann Surg.1996;224:531–543.
28.
29. Senkal M, Mumme A, Eickhoff U, et al. Early postoperative enterai immunonutrition: clinical outcome and cost-comparison analysis in surgical patients.Crit Care Med.1997;25:1489–1496.
29.
30. Senkal M, Zumtobel V, Bauer K-H, et al. Outcome and costeffectiveness of perioperative enteral immunonutrition in patients undergoing elective upper gastrointestinal tract surgery.Arch Surg.1999;134:1309–1316.
30.
31. Gianotti L, Braga M, Frei A, Greiner R, Di Carlo V. Health care resources consumed to treat postoperative infections: cost saving by perioperative immunonutrition.Shock.2000;14:325–330.
31.
32. Consensus recommendations from the U.S. Summit on Immune-Enhancing Enteral Therapy. JPEN J Parenter Enteral Nutr 2001;25(Suppl):S61-S62.
32.
33. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in combined medical-surgical intensive care units in the United States.Infect Control Hosp Epidemiol.2000;21:510–515.
33.
34. Angus DC, Linde-Zwirble WT, Clermont G, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.Crit Care Med.2003;31:1–11.
34.
35. Gann DS, Lilly MP. The neuroendocrine response to multiple trauma.World J Surg.1983;7:101–118.
35.
36. Kinney JM. Metabolic responses of the critically ill patient.Crit Care Clin.1995;11:569–585.
36.
37. Lin E, Calvano SE, Lowry SF. Inflammatory cytokines and cell response in surgery.Surgery.2000;127:117–126.
37.
38. Oberholzer A, Oberholzer C, Moldawer LL. Sepsis syndromes: understanding the role of innate and acquired immunity.Shock.2001;16:83–96.
38.
39. Fry DE. Multiple organ dysfunction syndrome: past, present and future.Surg Infect.2000;1:155–163.
39.
40. Angele MK, Faist E. Clinical review: immunodepression in the surgical patient and increased susceptibility to infection.Crit Care.2002;6:298–305.
40.
41. Kellum JA, Angus DC. Genetic variation and the risk of sepsis.Minerva Anestesiol.2003;69:245–253.
41.
42. Esposito S. Immune system and surgical site infection.J Chemother.2001;13:12–16.
42.
43. Grimble RF. Nutritional modulation of immune function.Proc Nutr Soc.2001;60:389–397.
43.
44. Chandra RK. Nutrition and the immune system: an introduction.Am J Clin Nutr.1997;66(Suppl):460S–463S.
44.
45. Mainous MR, Deitch EA. Nutrition and infection.Surg Clin North Am.1994;74:659–676.
45.
46. Gibbs J, Cull W, Henderson W, Daley J, Hur K, Khuri SF. Preoperative serum albumin level as a predictor of operative mortality and morbidity.Arch Surg.1999;134:36–42.
46.
47. Levy J. The effects of antibiotic use on gastrointestinal function.Am J Gastroenterol.2000;95(Suppl):S8–S10.
47.
48. Bengmark S. Gut microenvironment and immune function.Curr Opin Clin Nutr Metab Care.1999;2:83–85.
48.
49. Mainous MR, Tso P, Berg RD, Deitch EA. Studies of the route, magnitude, and time course of bacterial translocation in a model of systemic inflammation.Arch Surg.1991;126:33–37.
49.
50. Craven DE, Daschner FD. Nosocomial pneumonia in the intubated patient: role of gastric colonization.Eur J Clin Microbiol Infect Dis.1989;8:40–50.
50.
51. Bochicchio GV, Napolitano LM, Joshi M, et al. Persistent systemic inflammatory response syndrome is predictive of nosocomial infection in trauma.J Trauma.2002;53:245–250.
51.
52. Vincent JL. Nosocomial infections in adult intensive-care units.Lancet.2003;361:2068–2077.
52.
53. Wray CJ, Mammen JM, Hasselgren PO. Catabolic response to stress and potential benefits of nutrition support.Nutrition.2002;18:971–977.
53.
54. Heyland DK. Nutritional support in the critically ill patient: a critical review of the evidence.Crit Care Clin.1998;14:423–440.
54.
55. Alexander JW. Immunoenhancement via enteral nutrition.Arch Surg.1993;128:1242–1245.
55.
56. Bertolini G, Iapichino G, Radrizzani D, et al. Early enteral immunonutrition in patients with severe sepsis: results of an interim analysis of a randomized multicentre clinical trial.Intensive Care Med.2003;29:834–840.
56.
57. Gianotti L, Braga M, Nespoli L, Radaelli G, Beneduce A, Di Carlo V. A randomized controlled trial of preoperative oral supplementation with a specialized diet in patients with gastrointestinal cancer.Gastroenterology.2002;122:1763–1770.
57.
58. Atkinson S, Sieffert E, Bihari D. A prospective, randomized, double-blind, controlled clinical trial of enteral immunonutrition in the critically ill.Crit Care Med.1998;26:1164–1172.
58.
59. Bower RH, Cerra FB, Bershadsky B, et al. Early enteral administration of a formula (Impact®) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial.Crit Care Med.1995;23:436–449.
59.
60. Braga M, Gianotti L, Nespoli L, Radaelli G, Di Carlo V. Nutritional approach in malnourished surgical patients: a prospective randomized study.Arch Surg.2002;137:174–180.
60.
61. Braga M, Gianotti L, Vignali A, Cestari A, Bisagni P, Di Carlo V. Artificial nutrition after major abdominal surgery: impact of route of administration and composition of the diet.Crit Care Med.1998;26:24–30.
61.
62. Proceedings from the Summit on Immune-Enhancing Enteral Therapy. JPEN J Parenter Enteral Nutr. 2001;25(Suppl):S1-S60.
62.
63. Heyland DK, Novak F. Immunonutrition in the critically ill patient: more harm than good?JPEN J Parenter Enteral Nutr.2001;25(Suppl):S51–S56.
63.
64. Stechmiller JK, Childress B, Porter T. Arginine immunonutrition in critically ill patients: a clinical dilemma.Am J Crit Care.2004;13:17–23.
64.
65. Cynober L. Immune-enhancing diets for stressed patients with a special emphasis on agrinine content: analysis of the analysis.Curr Opin Clin Nutr Metab Care.2003;6:189–193.
65.
66. Galbán C, Montejo JC, Mesejo A, et al. An immune-enhancing enteral diet reduces mortality rate and episodes of bacteremia in septic intensive care unit patients.Crit Care Med.2000;28:643–648.
66.
67. Laupland KB, Zygun DA, Davies HD, Church DL, Louie TJ, Doig CJ. Incidence and risk factors for acquiring nosocomial urinary tract infection in the critically ill.J Crit Care.2002;17:50–57.
67.
68. Eggimann P, Pittet D. Infection Control in the ICU.Chest.2001;120:2059–2093.
68.
69. Heyland DK, Drover JW, Dhaliwal R, Greenwood J. Optimizing the benefits and minimizing the risks of enteral nutrition in the critically ill: role of small bowel feeding.JPEN J Parenter Enteral Nutr.2002;26(Suppl):S51–S55.
